TG Therapeutics, Inc. TGTX
The biggest changes in the 10-K filed Feb 27, 2026, in management's words
10-K, Item 7This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Net income
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
Revenue
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
“The increase in product revenue, net is driven by an increase in product shipments for BRIUMVI as a result of greater market penetration.”
Read it in the 10-K
Operating margin
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
“The increase in research and development expense was primarily due to an increase in manufacturing expense, including manufacturing and development costs incurred in connection with our subcutaneous ublituximab development work, increased clinical trial related expenses pertaining to our clinical pipeline, and increased personnel costs during the period ended December 31, 2025, as compared to the year ended December 31, 2024.”
Read it in the 10-K
What management said, year by year
The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)
Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.
Revenue
2 of 2 years explained-
FY 2025 +87.3%
“The increase in product revenue, net is driven by an increase in product shipments for BRIUMVI as a result of greater market penetration.”
Read it in the FY 2025 10-K -
FY 2024 +40.8%
“The increase in product revenue, net is driven by an increase in product shipments for BRIUMVI as a result of greater market penetration.”
Read it in the FY 2024 10-K
Operating margin
2 of 2 years explained-
FY 2025 +7.3 pts
“The increase in research and development expense was primarily due to an increase in manufacturing expense, including manufacturing and development costs incurred in connection with our subcutaneous ublituximab development work, increased clinical trial related expenses pertaining to our clinical pipeline, and increased personnel costs during the period ended December 31, 2025, as compared to the year ended December 31, 2024.”
Read it in the FY 2025 10-K -
FY 2024 +3.9 pts
“The increase in other research and development expense during the year ended December 31, 2024 was primarily attributable to manufacturing and development costs incurred in connection with our ublituximab subcutaneous development work, increased personnel and costs associated with the Precision License Agreement incurred during the period.”
Read it in the FY 2024 10-K
Net income
0 of 2 years explained-
FY 2025 +1812.4%
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 +84.5%
The FY 2024 MD&A has no sentence that names a cause for this change.
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K
Sources
The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.
Also
Financials: the numbers year by year.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TGTX/export.csv") into a cell.